Skip to main
OSTX
OSTX logo

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies Inc. has made significant regulatory progress with OST-HER2, enhancing its prospects for approval in treating metastatic osteosarcoma, which may lead to strong market potential. The company's management has demonstrated confidence in capturing a substantial addressable market, bolstered by a projected growth trajectory in the global veterinary oncology sector from $1.58 billion in 2024 to $4.77 billion by 2034. Furthermore, successful preliminary discussions with the NYSE and engagement with key opinion leaders, regulatory experts, and commercial manufacturers indicate a solid foundation for the operational framework of the upcoming entity focused on animal health.

Bears say

OS Therapies Inc faces significant challenges in its development pipeline due to the inherent limitations in treating osteosarcoma, which is characterized by poor responsiveness to receptor-level HER2 inhibition and other antibody-based therapies. The company's focus on a disease that is genetically unstable and immunologically “cold” raises concerns about the efficacy of its treatments and the potential market demand for these products. Furthermore, these scientific hurdles could negatively impact OS Therapies' prospects for successful clinical trials and commercialization, ultimately affecting its financial performance and stock valuation.

OSTX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 3 analysts, OSTX has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.